ArticleOncoimmunology2022

Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.

Michihisa Kono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.